Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1207 studies found for:    FDG
Show Display Options
Rank Status Study
1 Not yet recruiting Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma
Conditions: Malignant Neoplasms, Eye;   Glioblastoma;   Malignant Neoplasms, Brain;   Malignant Neoplasms, Central Nervous System
Interventions: Drug: FDG;   Procedure: PET/CT;   Procedure: MRI
2 Not yet recruiting Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia
Condition: Adrenal Gland Neoplasms
Interventions: Other: FDG positron emission tomography;   Other: Iodometomidate imaging
3 Recruiting FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Condition: Glioblastoma
Interventions: Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
4 Recruiting 18F-FDG PET/CT for IgG4-Related Disease
Condition: Autoimmune Disease
Intervention: Drug: 18F-FDG
5 Recruiting NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Carcinoma
Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Sodium Fluoride;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
6 Completed Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Conditions: Kidney Neoplasms;   Carcinoma, Renal Cell;   Kidney (Renal Cell) Cancer
Interventions: Procedure: FDG PET CT;   Procedure: DCE MRI;   Drug: F-18 Fluoro-deoxi-glucose;   Drug: Gadolinium-DTPA;   Drug: Sunitinib
7 Recruiting uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
Condition: Urinary Bladder Neoplasms
Interventions: Drug: Injection of 68Ga-NOTA-AE105;   Drug: Injection of 18F-FDG;   Device: Positron Emission Tomography and CT;   Device: Positron Emission Tomography and MRI
8 Recruiting Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer
Condition: FDG PET
Intervention: Device: FDG PET
9 Active, not recruiting 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
Condition: Pulmonary Hypertension
Interventions: Drug: 11C-acetate;   Drug: [18F]Fluoro-2-deoxy-2-D-glucose;   Other: Cardiac MRI
10 Enrolling by invitation Comparative Study With Different Tracers (18F-FDG and 68Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection
Condition: Infection and Inflammatory Reaction Due to Internal Joint Prosthesis
Intervention: Other: 68Ga-citrate and 18F-FDG PET scans
11 Terminated FDG-PET in Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Radiation: [18F]fluorodeoxyglucose;   Other: Molecular assays on biopsied tissue;   Device: positron emission tomography;   Device: computed tomography
12 Active, not recruiting 18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis
Condition: Infective Endocarditis
Intervention: Procedure: 18-FDG PET/CT scan
13 Active, not recruiting Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
Condition: Rectal Neoplasms
Interventions: Radiation: fludeoxyglucose F 18;   Device: positron emission tomography;   Device: magnetic resonance imaging;   Other: laboratory biomarker analysis
14 Completed
Has Results
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Other: 18F-fluoromisonidazole;   Radiation: fluorodeoxyglucose F 18;   Procedure: positron emission tomography;   Other: tissue oxygen measurement
15 Recruiting Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma
Conditions: Glioblastoma;   Glioma
Interventions: Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
16 Recruiting 18F-deoxyglucose (FDG) PET-CMD
Condition: Patients With Idiopathic Dilated Cardiomyopathy
Intervention: Drug: 18F-deoxyglucose (FDG)
17 Completed Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
Condition: Lymphoma
Intervention: Device: FDG-PET
18 Recruiting A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Conditions: Radiosensitive Stage IV Solid and Hematological Tumors With High FDG Uptake Not Responding to Standard of Care;   Lung Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Colon Cancer, Lymphomas, Sarcomas, Etc
Intervention: Radiation: FDG
19 Completed FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
Condition: Cholecystitis
Intervention: Drug: 18FDG (an FDA-approved radiopharmaceutical)
20 Recruiting Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Conditions: Cervical Cancer;   Endometrial Cancer
Interventions: Radiation: 18F-Fluorodeoxyglucose (18F-FDG);   Device: PET/CT imaging

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years